|
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
Mar 2021 |
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
May 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
Jul 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
Jun 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
May 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
Jan 2019 |
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
Jul 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
